Brief: NeuroBo Pharmaceuticals Receives Safety Review Committee Approval To Continue With Phase 2a Clinical Trial Evaluating DA-1241 For Treatment Of MASH
Brief: NeuroBo Pharmaceuticals Appoints Marshall Woodworth As CFO
Brief: NeuroBo Pharmaceuticals Appoints Marshall Woodworth As CFO
Nash Drug Developers Fall As Lilly's Weight: loss drug shows promise in trial
NASH drug developers fall as Lilly's drug shows promise in trial
U.S. STOCKS ON THE MOVE-Gold miners, Dorian LPG, Apple
Newscasts - Trading at Noon: Wall Street gains ground after Fed-driven selloff
U.S. STOCKS ON THE MOVE-CMS Energy, SunPower, Etsy
Brief: Neurobo Pharmaceuticals Announces FDA Clearance Of IND For Phase 1 Clinical Trial Of DA-1726
NeuroBo jumps on FDA nod to begin human trials for obesity drug
Brief: Neurobo Pharmaceuticals Full Data Readout Expected In 2H 2024
Brief: Neurobo Pharmaceuticals Regains Compliance With Nasdaq Minimum Price Requirement
U.S. STOCKS ON THE MOVE-Exxon Mobil, Energy Fuels, Barrick Gold
U.S. STOCKS ON THE MOVE-NeuroBo Pharma, EOG Resources, Nova LifeStyle
Brief: Neurobo Pharmaceuticals Submits IND Application To FDA For Phase 1 Clinical Trial Of DA-1726
NeuroBo Pharma rises after applying for obesity drug trial
Brief: Neurobo Pharmaceuticals Announces 1-For-8 Reverse Stock Split
Brief: Neurobo Pharmaceuticals - Appointed Marshall H. Woodworth As Co’S Acting CFO,
Brief: Neurobo Pharmaceuticals Doses First Patient In Its Phase 2A Clinical Trial Evaluating Da-1241